Structured treatment interruption: Approaches and risks

被引：18

作者：

Mark Dybul

机构：

[1] National Institutes of Health,National Institute of Allergy and Infectious Diseases

来源：

Current Infectious Disease Reports | 2002年 / 4卷 / 2期

关键词：

Human Immunodeficiency Virus; Human Immunodeficiency Virus Infection; Treatment Interruption; Human Immunodeficiency Virus Replication; Plasma Viremia;

D O I：

10.1007/s11908-002-0059-2

中图分类号：

学科分类号：

摘要：

Although highly active antiretroviral therapy suppresses HIV replication resulting in extraordinary clinical benefits, toxicity, adherence difficulties, and the monetary cost of medications limit the long-term effectiveness and availability of therapy for many HIV-infected individuals. Strategies to interrupt therapy have been proposed as a means to enhance the sustainability of antiretroviral treatment. Widely different approaches with varied patient populations, theoretical concepts, and clinical designs are frequently lumped together as "structured treatment interruptions." This review summarizes the approaches and risks of treatment interruptions in HIV infection. Currently, none of these strategies can be recommended in standard clinical practice.

引用

页码：175 / 180

页数：5

共 132 条

[1]

Chun TW(1997)Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci U S A 94 13193-13197

[2]

Stuyver L(1999)HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy Lancet 353 119-120

[3]

Mizell SB(1999)Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy N Engl J Med 340 1614-1622

[4]

Natarajan V(1999)Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy N Engl J Med 340 1605-1613

[5]

Bosche M(1999)HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc Natl Acad Sci U S A 96 15109-15114

[6]

Metcalf JA(1999)Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy AIDS 13 F79-F86

[7]

Furtado MR(1999)HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group AIDS 13 677-683

[8]

Callaway DS(2000)Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression AIDS 14 1357-1363

[9]

Phair JP(1999)Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors AIDS 13 F63-F70

[10]

Zhang L(2001)Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database AIDS 15 231-239

← 1 2 3 4 5 6 7 8 9 10 →